Scholarlink

Background <p>Monocyte-to-HDL Ratio (MHR) biomarker reflects monocyte-driven inflammation and HDL’s anti-inflammatory properties. MHR’s reference ranges and prognostic utility remain undefined. We establish normal MHR reference ranges and examine its association with inflammatory diseases and mortality.</p> Methods <p>Using NHANES data (1999–2018, 2021–2023), two sets of sex-specific MHR reference ranges were generated using two healthy adult populations (monocyte count: 6,757; monocyte percentage: 6,817). Further analyses utilized MHR by monocyte count for more straightforward interpretation. Adjusted associations between MHR and inflammatory diseases were assessed in 49,929 adults, and disease-specific mortality in 35,781.</p> Results <p>The 2.5th–97.5th percentiles for MHR by monocyte count were 0.175 (90% CI: 0.167–0.184) to 0.709 (90% CI: 0.690–0.727) in males and 0.135 (90% CI: 0.130–0.140) to 0.511 (90% CI: 0.503–0.520) in females, with similar trends for MHR by monocyte percentage. High MHR was most strongly associated with diabetes (aOR = 1.76, <i>p</i> &lt; 0.001) and cardiovascular disease (aOR = 1.69, <i>p</i> &lt; 0.001), while mortality risk was highest for kidney disease (aHR = 3.13, <i>p</i> &lt; 0.001) and diabetes (aHR = 2.26, <i>p</i> &lt; 0.001).</p> Conclusion <p>MHR is a feasible and accessible biomarker of inflammation and lipid dysregulation that can be derived from routine laboratory tests and shows strong associations with cardiometabolic diseases and disease-related mortality.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Monocyte-to-HDL ratio (MHR) as a novel biomarker: reference ranges and associations with inflammatory diseases and disease-specific mortality

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月23日

查看全文
  • Ahmed Arabi,
  • Alaa Abdelhamid,
  • Dima Nasrallah,
  • Yaman Al-Haneedi,
  • Deemah Assami,
  • Raneem Alsheikh,
  • Susu M. Zughaier

摘要

Background

Monocyte-to-HDL Ratio (MHR) biomarker reflects monocyte-driven inflammation and HDL’s anti-inflammatory properties. MHR’s reference ranges and prognostic utility remain undefined. We establish normal MHR reference ranges and examine its association with inflammatory diseases and mortality.

Methods

Using NHANES data (1999–2018, 2021–2023), two sets of sex-specific MHR reference ranges were generated using two healthy adult populations (monocyte count: 6,757; monocyte percentage: 6,817). Further analyses utilized MHR by monocyte count for more straightforward interpretation. Adjusted associations between MHR and inflammatory diseases were assessed in 49,929 adults, and disease-specific mortality in 35,781.

Results

The 2.5th–97.5th percentiles for MHR by monocyte count were 0.175 (90% CI: 0.167–0.184) to 0.709 (90% CI: 0.690–0.727) in males and 0.135 (90% CI: 0.130–0.140) to 0.511 (90% CI: 0.503–0.520) in females, with similar trends for MHR by monocyte percentage. High MHR was most strongly associated with diabetes (aOR = 1.76, p < 0.001) and cardiovascular disease (aOR = 1.69, p < 0.001), while mortality risk was highest for kidney disease (aHR = 3.13, p < 0.001) and diabetes (aHR = 2.26, p < 0.001).

Conclusion

MHR is a feasible and accessible biomarker of inflammation and lipid dysregulation that can be derived from routine laboratory tests and shows strong associations with cardiometabolic diseases and disease-related mortality.